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Department of Neurology and Epileptology, The Children’s Memorial Health Institute, Warsaw, PolandProgress in epilepsy treatment in last decades of the
twentieth century included a number of new antiepileptic
drugs that were expected to reduce the number of patients
with drug-resistant epilepsy. However, it soon became
obvious that, in spite of the improving safety of antiepileptic
treatment, the efﬁcacy of new agents was not much better
than the old drugs. The number of patients with drug-
resistant epilepsy decreased little, and their outcome has
not been improved.
The search for new therapeutic approaches and the
emergence of clinically relevant animal models of epilepsy
led to a renewed interest in the process of epileptogenesis.
This cascade of molecular and cellular alterations (including
changes in expression and function of receptors and ion
channels) begins with an insult, brain injury, or genetic
predisposition. There is often a latent period lasting weeks
to months before the onset of seizures, followed by the
development of clinical epilepsy and its comorbidities. This
latent period of epilepsy development may offer a time
window when an appropriate medication may stop or
modify the epileptogenic process.
Recent animal studies using the genetic models proved
that early (antiepileptogenic) therapeutic intervention dur-
ing this latent period might prevent the development of
epilepsy. In an epileptic double mutant rat (spontaneously
epileptic rat; zi/zi, tm/tm) that presents recurring tonic and
absence-like seizures in response to mild sensory stimula-
tion, Yan et al.1 used levetiracetam for threeweeks before the
expected time of seizure onset. Such preventative treatment
with levetiracetam resulted in a signiﬁcant decrease in the
incidence of both types of seizures, indicating a disease-
modifying effect.1 Another genetic model of human
absence epilepsy was used by Blumenfeld et al.2 Wistar Al-
bino Glaxo/Rij rats that exhibit spontaneous spike-waveArticle History:
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with oral ethosuximide from postnatal day 21 to 5months of
age. Early treatment with ethosuximide led to a persistent
suppression of seizures, even several months after therapy
withdrawal. Prolonged antiepileptogenic treatment in this
genetic model had a beneﬁcial effect on white matter
microstructure inWistar Albino Glaxo/Rij rats as observed by
diffusion tensor imaging studies.3 These experiments with
ethosuximide and levetiracetam in genetic models seem to
demonstrate that epilepsy prevention is possible and that
antiepileptogenic treatment may provide a new strategy for
preventing epilepsy in susceptible individuals.
Several completed clinical trials in humans have
demonstrated that administration of conventional antiepi-
leptic drugs, such as phenytoin, phenobarbital, carbamaz-
epine, or valproate, in patients after traumatic brain injury
failed to prevent the development of epilepsy.4 However, it
seems likely that these studies were not properly designed
to answer the question at hand, and the drugs were not
selected to have antiepileptogenic activity.5
The immature brain seems to be especially vulnerable to
seizures, but it may also be particularly susceptible to
antiepileptogenic treatment. Talos et al.6 used a rodent
model of acute hypoxia-induced neonatal seizures to
determine how seizures alter mTOR complex 1 signaling,
contributing to epileptic networks and autistic-like
behavior in later life. They demonstrated that inhibition of
mTOR complex 1 immediately before and after seizures
reversed an early increase in glutamatergic neurotrans-
mission and seizure susceptibility and attenuated later life
epilepsy and autistic-like behavior.
The impact of effective antiepileptogenic treatment on
the immature brain is particularly apparent in children less
than two years of age. Clinical settings provide an especially
good opportunity to prevent epilepsy and its comorbidities
in some genetic or developmental defects with a high risk of
epilepsy during the ﬁrst years of life. Prophylactic treatment
with phenobarbitone of 16 infants with Sturge-Weber
syndrome resulted in decreased epilepsy (P < 0.01) and
mental retardation (P < 0.05) in comparison to 21 children
treated in the standard manner (i.e., after the onset of
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treatment has been observed in our study in infants with
tuberous sclerosis complex (TSC). A prospective study of 14
children treated with vigabatrin due to paroxysmal activity
on EEG in the ﬁrst months of life demonstrated a lower
incidence of drug-resistant epilepsy and higher intelligence
quotient score at 24 months of age compared with 31
traditionally treated children (7.1% versus 41.9%, P < 0.05;
and 92.3% versus 68.7%, P < 0.05, respectively).8
The recently published “practical clinical deﬁnition of
epilepsy” made also a step forward toward anti-
epileptogenic treatment by allowing the diagnosis of epi-
lepsy after a single seizure in many situations with a
probability of another seizure exceeding 60%.9 However,
there are still no recommendations for pre-emptive man-
agement of speciﬁc groups of patients with a very high
incidence of epilepsy, well recognized natural course of the
disease, and established severe epilepsy comorbidities such
as mental retardation and autism. In conditions such as TSC,
Sturge-Weber syndrome, Angelman syndrome, and Rett
syndromewith an incidence of epilepsy over 60% in the ﬁrst
year of life, the antiepileptogenic treatment should be
considered before the onset of clinical seizures, when epi-
leptogenesis is early in progress.
A search of valid biomarkers to aid the identiﬁcation of a
point of no return in the epileptogenesis process is a major
challenge for clinicians. In our experience with over 50 TSC
infants followed since soon after birth with video EEGs per-
formed every 4 weeks, those who developed paroxysmal ac-
tivity demonstrated seizures within 2-3 weeks.10 A
determination of EEG characteristics as well as the molecular
and neuroimaging biomarkers allowing identiﬁcation of chil-
dren with high risk of epilepsy is critical. Currently, such
studies are ongoing within the long-term, prospective study
evaluating clinical and molecular biomarkers of EPIlepto-
genesiS in a genetic model of epilepsyeTuberous SclerOsis
ComPlex (EPISTOP), the large-scale collaborative project
within the 7th Framework Programme of European Commu-
nity. EPISTOP is a multicenter, prospective study of epilepto-
genesis in TSC infants, starting from its latent phase before
seizures onset and extending to the development of drug-
resistance and epilepsy neuropsychiatric comorbidities. The
comprehensive analysis of possible epileptogenesis bio-
markers in EPISTOP project includes a wide range of clinical,
electrophysiological, neuroimaging, neuropsychologic, andmolecular (genomics, transcriptomics, proteomics, metab-
olomics, epigenetics) investigations.Theprojecthas justbegun
and will last for ﬁve years.
Prevention of epilepsy in individuals at risk or the
modiﬁcation of the disease outcome is one of the major
United States The National Institute of Neurological Disor-
ders and Stroke/ National Institutes of Health Epilepsy
Research benchmarks and also a research priority of the
European scientiﬁc community. Such a goal is particularly
meaningful for pediatric neurologists, the physicians who
are often in the optimal position to alter the natural course
of disease and improve the quality of life of their patients
and their families.
The work reported in this paper was partially supported by the 7th Framework
Programme of European Commission within the large-scale integrating project
EPISTOP (www.epistop.eu).
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